# US 2017/0283377 A1 · Androgen receptor modulators and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283377 A1
- Document ID: US20170283377A1
- Status: Published application
- Kind: A1
- Application number: 15/626,526
- Filed: 2017-06-19
- Published: 2017-10-05
- Earliest claimed: 2014-05-30
- Assignees: British Columbia Cancer Agency Branch; The University of British Columbia
- Applicants: British Columbia Cancer Agency Branch; The University of British Columbia
- Inventors: Luping YAN; Raymond J. ANDERSEN; Marianne Dorothy SADAR; Nasrin R. MAWJI; Carmen Adriana Banuelos
- Web page: https://patentgrep.com/patent/US20170283377A1

## CPC

- C07D 207/38: 2-Pyrrolones
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R6, Y1 and Y2 are as defined herein, and wherein at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

## Claims

### Claim 1

A compound having the following structure (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
Y1 and Y2 are each independently O or S;
R1 is H, C1-C6 alkyl or C1-C6 haloalkyl;
R2 is H, —C(═O)R7 or —S(O)nR8;
at least one of R3 or R4 is a straight-chain C1-C6 haloalkyl, and the other one of R3 or R4 is C1-C6 alkyl or C1-C6 haloalkyl;
R5 and R6 are each independently H, OH, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;
R7 is C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;
R8 is C1-C6 alkyl or C1-C6 haloalkyl;
is a carbon-carbon double bond or a carbon-carbon single bond, such that all valences are satisfied; and
n is 0, 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound has one of the following structures (Ia), (Ib), (Ic) or (Id):

### Claim 3 (depends on 1, 2)

The compound of any one of claims 1 or 2, wherein Y1 is O.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Y2 is O.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein R1 is H.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R2 is H.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R2 is —C(═O)R7.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R7 is C1-C6 alkyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein C1-C6 alkyl is ethyl, t-butyl or

### Claim 10 (depends on 7)

The compound of claim 7, wherein R7 is C1-C6 alkoxy.

### Claim 11 (depends on 10)

The compound of claim 10, wherein C1-C6 alkoxy is t-butoxy.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R2 is —S(O)nR8.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R8 is C1-C6 alkyl.

### Claim 14 (depends on 12)

The compound of claim 12, wherein C1-C6 alkyl is ethyl.

### Claim 15 (depends on 12, 13, 14)

The compound of any one of claims 12-14, wherein n is 2.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, wherein R5 is C1-C6 alkoxy.

### Claim 17 (depends on 16)

The compound of claim 16, wherein C1-C6 alkoxy is methoxy.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17, wherein R6 is H.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R3 is a straight-chain C1-C6 haloalkyl, and R4 is C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R4 is C1-C6 haloalkyl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein C1-C6 haloalkyl is a branched C1-C6 haloalkyl.

### Claim 22 (depends on 20)

The compound of claim 20, wherein C1-C6 haloalkyl is a straight-chain C1-C6 haloalkyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is a straight-chain C1-C6 haloalkyl, and R3 is C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R3 is C1-C6 haloalkyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein C1-C6 haloalkyl is a branched C1-C6 haloalkyl.

### Claim 26 (depends on 24)

The compound of claim 24, wherein C1-C6 haloalkyl is a straight-chain C1-C6 haloalkyl.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein at least one of R3 or R4 is a straight-chain C1-C6 chloroalkyl, and the other one of R3 or R4 is C1-C6 chloroalkyl.

### Claim 28 (depends on 27)

The compound of claim 27, wherein C1-C6 chloroalkyl comprises a perchloro-substituted carbon.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1-28, wherein R3 or R4, or both, is 3,3,3-trichloropropyl.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, wherein is a carbon-carbon double bond.

### Claim 31 (depends on 1)

The compound of claim 1, wherein the compound has one of the following structures:

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition comprising a compound of any one of claims 1 to 31 and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition comprising a compound of any one of claims 1 to 31, an additional therapeutic agent and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy or age-related macular degeneration.

### Claim 35 (depends on 33)

The pharmaceutical composition of claim 33, wherein the additional therapeutic agent is enzalutamide, Galeterone, ARN-509, ODM-201, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6 258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 2826 0, SKF105,111, Radium 233 or prednisone.

### Claim 36 (depends on 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 32-35, wherein the pharmaceutical composition is formulated for topical administrations.

### Claim 37 (depends on 32, 33, 34, 35, 36)

Use of the pharmaceutical composition of any one of claims 32-36, for modulating androgen receptor (AR) activity.

### Claim 38 (depends on 37)

The use of claim 37, wherein modulating androgen receptor (AR) activity is in a mammalian cell.

### Claim 39 (depends on 37, 38)

The use of any one of claims 37 or 38, wherein modulating androgen receptor (AR) activity is for treatment of at least one indication selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration.

### Claim 40 (depends on 39)

The use of claim 39, wherein the indication is prostate cancer.

### Claim 41 (depends on 40)

The use of claim 40, wherein the prostate cancer is castration resistant prostate cancer.

### Claim 42 (depends on 40)

The use of claim 40, wherein the prostate cancer is androgen-dependent prostate cancer.

### Claim 43 (depends on 32, 33, 34, 35, 36)

A method for modulating androgen receptor (AR) activity, the method comprising administering the pharmaceutical composition of any one of claims 32-36 to a subject in need thereof.

### Claim 44 (depends on 43)

The method of claim 43, wherein modulating androgen receptor (AR) activity is for the treatment of one or more of the following: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration.

### Claim 45 (depends on 44)

The method of claim 44, wherein the method is for treatment of prostate cancer.

### Claim 46 (depends on 45)

The method of claim 45, wherein the prostate cancer is castration resistant prostate cancer.

### Claim 47 (depends on 45)

The method of claim 45, wherein the prostate cancer is androgen-dependent prostate cancer.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the administration in topical.

### Claim 49 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the administration in intravenous.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method for modulating androgen receptor (AR) activity, the method comprising administering the compound of any one of claims 1-31 and an additional therapeutic agent to a subject in need thereof.

### Claim 51 (depends on 50)

The method of claim 50, wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy or age-related macular degeneration.

### Claim 52 (depends on 50)

The method of claim 50, wherein the additional therapeutic agent is enzalutamide, Galeterone, ARN-509, ODM-201, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6 258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 2826 0, SKF105,111, Radium 233 or prednisone.
